Literature DB >> 8123488

A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.

P A Pasanen1, M Eskelinen, K Partanen, P Pikkarainen, I Penttilä, E Alhava.   

Abstract

The aim of this study was to assess by a stepwise multivariate discriminant analysis the value of four current serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50 and CA 242 and tissue polypeptide antigen (TPA) - and a new serum tumour marker, tissue polypeptide specific antigen (TPS), in the diagnosis of pancreatic cancer. The serum values were measured in a prospective series of patients with jaundice, with unjaundiced cholestasis and with a suspicion of chronic pancreatitis or a pancreatic tumour (n = 193). There were 24 patients with a cancer of the pancreas and two patients with a cancer of the papilla of Vater in this series. Our results showed that CA 50 (P < 0.001) and TPA (P < 0.01) were the best marker tests in predicting pancreatic malignancy. Also, the TPS (P = 0.07) and CA 242 (P = 0.08) tests showed marginally significant independent discriminating power, while the CEA test did not (P = 0.12). In order to sum up the contributions of different markers, a diagnostic score (DSI) was developed. The discrimination function was: DS1 = CA 50 x 1.75 + TPA x 0.62 + TPS x (-0.37) + CA 242 x (-1.21). The sensitivity of DS1 in detecting pancreatic cancer was 36% with a specificity of 90% and an efficiency of 82%. When the combination of CA 50 and TPA was used as a test, the discrimination function (DS2) was: DS2 = CA 50 x 0.69 + TPA x 0.67. The sensitivity of DS2 was 44% with a 88% specificity and an efficiency of 82%. According to this analysis, the further advantage gained by a computer-aided scoring system seems to be limited, since despite the considerably high specificity and efficiency its sensitivity remained low. In the present analysis the best combination in diagnosing pancreatic cancer was the combination of CA 50 and TPA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123488      PMCID: PMC1968866          DOI: 10.1038/bjc.1994.102

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat-labile tumor antigen.

Authors:  B BJORKLUND; V BJORKLUND
Journal:  Int Arch Allergy Appl Immunol       Date:  1957

3.  On the use and computation of likelihood ratios in clinical chemistry.

Authors:  A Albert
Journal:  Clin Chem       Date:  1982-05       Impact factor: 8.327

4.  Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.

Authors:  C Haglund; P Kuusela; H Jalanko; P J Roberts
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

5.  Specificity and basis of the tissue polypeptide antigen.

Authors:  B Björklund; V Björklund
Journal:  Cancer Detect Prev       Date:  1983

6.  A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer.

Authors:  L Benini; G Cavallini; D Zordan; P Rizzotti; L Rigo; G Brocco; L Perobelli; M Zanchetta; P Pederzoli; L A Scuro
Journal:  Pancreas       Date:  1988       Impact factor: 3.327

7.  Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.

Authors:  P Masson; B Pålsson; A Andrén-Sandberg
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

8.  Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.

Authors:  P Kuusela; C Haglund; P J Roberts
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

9.  Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.

Authors:  C Haglund
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

10.  Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

Authors:  C Haglund; J Lindgren; P J Roberts; P Kuusela; S Nordling
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

View more
  4 in total

Review 1.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

Review 2.  Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview.

Authors:  S Bünger; T Laubert; U J Roblick; J K Habermann
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-31       Impact factor: 4.553

Review 3.  Circulating blood group related carbohydrate antigens as tumour markers.

Authors:  T F Orntoft; E Bech
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

4.  Novel tumour markers: a diagnostic role in pancreatic cancer?

Authors:  J E Roulston
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.